Renal Cell Carcinoma – Diagnostic and Staging Recommendations (ESMO)
Imaging‑Based Diagnosis
- Over 50 % of renal cell carcinomas are discovered incidentally on imaging performed for unrelated reasons (ultrasound, CT, or MRI). Strong recommendation (European Society for Medical Oncology). [1][2]
- Imaging is the primary diagnostic tool: abdominal ultrasound is the first‑line modality, followed by contrast‑enhanced CT for confirmation and accurate staging. Strong recommendation (ESMO). [1][3]4
Histopathologic Confirmation (Biopsy)
- Core‑needle biopsy of a renal mass provides histopathologic confirmation with high sensitivity and specificity; it is especially advised before ablative therapies and in patients with metastatic disease prior to initiating systemic treatment. Strong recommendation (ESMO). [1][2]
Laboratory Tests for Prognostic Stratification (Not Diagnostic)
- Serum creatinine, hemoglobin, complete blood count, LDH, C‑reactive protein, and corrected calcium are employed in prognostic scoring systems such as the IMDC risk model; they are not diagnostic biomarkers. Moderate recommendation (ESMO). [1][3]
Tissue Immunohistochemistry for Histologic Subtyping
- Cytokeratin 7 (CK7) shows diffuse positivity in chromophobe renal carcinoma and is negative or only focally positive in oncocytoma, aiding differential diagnosis. Evidence level: moderate. [2][7]8
- Immunohistochemistry and fluorescence in‑situ hybridisation (FISH) for TFE3/TFEB are recommended to detect MiT family translocations in young patients with suspected translocation‑associated renal tumors. Evidence level: moderate. [2][7]8
Paraneoplastic Syndromes Suggestive of RCC
- Stauffer syndrome (laboratory hepatic abnormalities without hepatic metastases) can be a presenting feature of renal cell carcinoma. Evidence level: moderate. 1
- Unexplained fever may accompany RCC and often resolves after tumor resection. Evidence level: moderate. 1